Nitric Acid

Nitric Acid

SCHEMBL4166300

COCCNS(=O)(=O)c1ccc(NC(=N)N)cc1.O=[N+]([O-])O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.55
LMNA P02545 6/20 0.55
HPGD P15428 3/20 0.55
KDM4E B2RXH2 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 1/20 0.55
MAPT P10636 1/20 0.55
RAB9A P51151 1/20 0.55
NAMPT P43490 2/20 0.51
ALOX15 P16050 1/20 0.50
HTT P42858 1/20 0.50
POLB P06746 2/20 0.47
PKM P14618 4/20 0.46
MEN1 O00255 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPK1 P28482 2/20 0.43
SYK P43405 1/20 0.43
S1PR1 P21453 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161233 0.94 ALDH1A1 (0.61) ALDH1A1LMNAHPGDKDM4ESMN1; SMN2
SCHEMBL4165927 0.79 ALDH1A1 (0.50) ALDH1A1LMNAHPGDKDM4ESMN1; SMN2
SCHEMBL4152007 0.77 ALDH1A1 (0.54) ALDH1A1LMNASMN1; SMN2RAB9ANAMPT
Nitric Acid SCHEMBL2076286 0.76 TGM2 (0.47) ALDH1A1LMNAMAPTKMT2AGAA
SCHEMBL4158719 0.76 LMNA (0.58) ALDH1A1LMNAKDM4ESMN1; SMN2NPC1
SCHEMBL3024109 0.74 ALDH1A1 (0.69) ALDH1A1LMNAHPGDKDM4ESMN1; SMN2
SCHEMBL19454509 0.74 ALDH1A1 (0.73) ALDH1A1LMNAHPGDKDM4ESMN1; SMN2
SCHEMBL27893517 0.73 ALDH1A1 (0.67) ALDH1A1LMNAHPGDKDM4ESMN1; SMN2
Nitric Acid SCHEMBL5354098 0.73 ALDH1A1 (0.52) ALDH1A1LMNAHPGDSMN1; SMN2NPC1
SCHEMBL25993003 0.72 PRSS1 (0.43) ALDH1A1KDM4ESMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 ALDH1A1 2743/4885LMNA 1768/4885HPGD 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.